PremiumRatingsRevolution Medicines Earns Buy as Strong RAS Portfolio Data, Robust Launch Prep, and $5.4B Capital Base Drive Price Target Increase to $2914h agoRVMD
Revolution Medicines Earns Buy as Strong RAS Portfolio Data, Robust Launch Prep, and $5.4B Capital Base Drive Price Target Increase to $291
PremiumRatingsRalph Schackart Reiterates Buy on DoorDash, Citing AI-Driven Efficiency, Autonomous Delivery Initiatives, and Growing DashPass Memberships5h agoDASH
Ralph Schackart Reiterates Buy on DoorDash, Citing AI-Driven Efficiency, Autonomous Delivery Initiatives, and Growing DashPass Memberships
PremiumMarket NewsAMD Stock Fell after Q2 Earnings, but Jefferies and Truist Raised Price Targets. Here’s Why9h agoAMD
PremiumBlurbsAnalysts Conflicted on These Consumer Cyclical Names: DoorDash (DASH) and EVgo (EVGO)9h agoDASHEVGO